The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Fri., May. 29, 10:07 AM

Slide #17. Agenus Secondary Offering

Company: Agenus (NASDAQ:AGEN)
Date announced: 5/20/2015
Shares Offered: 11,000,000
Date of Pricing: 5/21/2015
Price Per Share: $6.30
Secondary Offering Details: Agenus Inc. (NASDAQ:AGEN), an immunotherapy company developing immune-oncology checkpoint modulators (CPMs), heat shock protein peptide-based vaccines and immune adjuvants, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. Agenus intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of its common stock offered in the public offering. All of the shares of common stock to be sold in the offering will be offered by Agenus. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. - updated 5/21 - Agenus Inc. (NASDAQ:AGEN), an immunology company developing innovative treatments for cancers and other diseases, today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $6.30 per share. The gross proceeds from the offering to Agenus are expected to be $69,300,000, before deducting underwriting discounts and commissions and estimated offering expenses payable by Agenus. Agenus has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of its common stock at the public offering price, less the underwriting discount. All of the shares of common stock to be sold in the offering will be sold by Agenus.

Agenus is a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators, heat shock protein vaccines and adjuvants. Co. is focused on immunotherapeutic products based on its core platform technologies with multiple product candidates advancing through the clinic, including several product candidates that have advanced into late-stage clinical trials through corporate partners. Co.'s core technology portfolio consists of its Checkpoint Antibody Program, its Heat Shock Protein Platform, and its Saponin Platform.
Open the AGEN Page at The Online Investor »

Company Name:  Agenus Inc
Sector:  Biotechnology
Number of ETFs Holding AGEN:  13
Total Market Value Held by ETFs:  $12.29M
Total Market Capitalization:  $518.00M
% of Market Cap. Held by ETFs:  2.37%

Open the AGEN Page at The Online Investor (in a new window) »

May 29, 2015    10:07 AM Eastern
Quotes delayed 20 minutes

Strong Buy (4.00 out of 4)
97th percentile
(ranked higher than approx. 97% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | | Copyright © 1998 - 2015, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.